Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.63 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.63 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7608248 | 0.94 | CYP4A11 (0.64) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL7611304 | 0.88 | CYP4A11 (0.58) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL10661898 | 0.80 | CYP4A11 (0.69) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL2654656 | 0.80 | CYP4A11 (0.97) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL14660877 | 0.80 | CYP4A11 (0.73) | CYP4A11CYP4F2ALDH1A1MAPTTHRA | |
| SCHEMBL6069166 | 0.80 | CYP4A11 (0.73) | CYP4A11CYP4F2ALDH1A1MAPTTHRA | |
| SCHEMBL2653147 | 0.80 | CYP4A11 (0.97) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL10986414 | 0.80 | CYP4A11 (0.73) | CYP4A11CYP4F2ALDH1A1MAPTTHRA | |
| SCHEMBL10610263 | 0.80 | CYP4A11 (0.73) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL12814607 | 0.80 | CYP4A11 (0.73) | CYP4A11CYP4F2ALDH1A1MAPTTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964534-B2 | Nuclear magnetic resonance assembly of chemical entities using advanced antenna probes | TRIAD LIQUIDATING COMPANY, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110118148-A1 | NUCLEAR MAGNETIC RESONANCE ASSEMBLY OF CHEMICAL ENTITIES USING ADVANCED ANTENNA PROBES | TRIAD LIQUIDATING COMPANY, LLC | 2011-05-19 | — | — | US | disclosed |
| US-7653490-B2 | Nuclear magnetic resonance assembly of chemical entities | Triad Liquidating Company LLC (US) | 2010-01-26 | — | — | US | disclosed |
| US-20030113751-A1 | Nuclear magnetic resonance assembly of chemical entities | TRIAD LIQUIDATING COMPANY, LLC | 2003-06-19 | — | — | US | disclosed |
| WO-2003023392-A1 | NUCLEAR MAGNETIC RESONANCE ASSEMBLY OF CHEMICAL ENTITIES | TRIAD THERAPEUTICS, INC (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118148-A1 | NUCLEAR MAGNETIC RESONANCE ASSEMBLY OF CHEMICAL ENTITIES USING ADVANCED ANTENNA PROBES | AURKAIP1, MRPS27, ATRIP | CYP4A11 4796/4885CYP4F2 2424/4885LOXL2 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.